Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Primary Care
How often do you offer repeat imaging for patients with life expectancy>10 years and BCR prostate cancer with PSADT>10 months while they are on observation?
Related Questions
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
What time frame, number of PSAs, and calculator do you use for calculating PSA doubling times?
Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
Would the presence of only mature teratoma on orchiectomy specimen lead you to consider upfront RPLND followed by adjuvant chemotherapy as opposed to upfront chemotherapy in a patient with bulky para-aortic nodal disease (cN3) and AFP/beta-HCG elevation?
For patients starting Pluvicto, do you have patients stop their ARPI?
How do you approach patients who are inappropriately worried/fixated on a test result that is flagged as abnormal but not clinically significant?
How would do manage stage II/III Muscle invasive bladder cancer with large cell neuroendocrine histology?
What are your top takeaways from ASCO GU 2025?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
